Tag:

Biogen Idec

Latest Headlines

Latest Headlines

Alkermes takes its Tecfidera beater into clinical trials for MS

Alkermes has its sights set on Biogen Idec's blockbuster multiple sclerosis treatment, advancing a me-better candidate of its own into Phase I study.

U-turn from U.K.'s NICE boosts Biogen's high-flying Tecfidera

Biogen Idec's multiple sclerosis pill Tecfidera has been steamrolling since it hit the U.S. market last April. And now, it's poised to pad global sales with a victory in the U.K., whose cost watchdog has given it the OK in final guidance after flip-flopping on a February decision not to endorse the drug.

Biogen prices new, long-acting hemophilia med with eye on patient-switching

Back in April, Biogen Idec stirred up the hemophilia B market by pricing its long-acting newcomer Alprolix on par with older meds. Now, it's doing the same with April approval Eloctate, another long-lasting drug--but in a hemophilia A market where the stakes are much, much higher.

Biogen MS blockbuster Tecfidera earns high marks for safety

Biogen's multiple sclerosis drug Tecfidera has racked up $1.38 billion in sales since its launch last April, and now the company can claim another feather in the drug's cap: It has the best safety profile of any of its peers. That's the conclusion of a new report out from AdverseEvents, which analyzes side-effects data filed with the FDA.

J&J, GSK meds join Sovaldi, Tecfidera in blockbuster-to-be crowd

New drug approvals may have dropped from 2012's high of 43 to 35 last year. But that doesn't mean 2013's crop lacks superstars.

Once-monthly MS drug from Biogen Idec, AbbVie clears Phase III hurdle

Biogen Idec and AbbVie announced Monday morning that their once-monthly multiple sclerosis drug daclizumab has cleared key hurdles in a Phase III study, setting the stage for a marketing pitch to regulatory authorities.

Analysts: Biogen's second long-acting hemophilia med headed for blockbuster strata

With Friday's FDA nod for Eloctate, Biogen Idec won approval for its second long-acting hemophilia treatment this year. But while both will shake up their respective markets, this one--a hemophilia A treatment--will be where the money is.

Biogen Idec racks up another blockbuster FDA approval, this time for hemophilia

Just a couple of months after scoring a groundbreaking approval for its new hemophilia B drug, Biogen Idec has scored another FDA OK for Eloctate, a hemophilia A drug targeting a much broader blockbuster market.

Biogen, Array strike preclinical autoimmune disease pact

Array BioPharma has formed a drug discovery pact with Biogen Idec to develop inhibitors targeting a novel kinase for the treatment of autoimmune disorders.

Slumping Array aligns with Biogen on early autoimmune R&D

Array BioPharma has watched its shares fall steadily earthward since ex-partner Amgen backed out of a diabetes deal last summer, but a new deal with Big Biotech Biogen Idec sent the company up about 5% on renewed hopes for its early-stage R&D efforts.